Viztek sees impressive 45% year-over-year revenue growth

February 5, 2014 (HIMSS Booth #4388) – Raleigh, NC - Viztek, the leading provider of complete digital software and hardware diagnostic imaging solutions, today announced 45 percent year-over-year revenue growth from the 2011-2013 calendar years. Strong DR and PACS sales supported this, with 20 percent growth in DR, and 15 percent growth in software. The PACS replacement market was particularly strong for the company, with 75 replacements in 2013, a year when Viztek also saw a significant jump in its customer base of hospitals with more than 200 beds.

“Our innovation and ability to move quickly are fueling our remarkable growth at a time when many, to the contrary of us, are struggling in this competitive market,” explained Josip Cermin, Founder and President, Viztek. “With a new FDA approval at the start of 2014, combined with an expanded DR line-up and a brand new EHR, we are poised to repeat this successful growth again in fiscal year 2014. We have a talented and energetic team fueling our surging accomplishments.”

End-to-End Hospital Solutions

A key focus for Viztek during 2013 was the delivery of end-to-end digital solutions for hospitals. Instrumental to successful expansion beyond the small market and into community hospitals is a robust DR line up including the Leggera Wireless DR detector. The industry’s lightest ISO 4090 cassette size wireless DR panel leap-frogged other DR detectors with its advanced technologies for image storage and unrivaled productivity. With nearly 300 software sales, 75 of which were replacement PACS installations, Viztek also saw impressive demand for its Opal suite of products, replacing legacy PACS with Viztek’s Opal-RAD PACS.  A new sweet spot target for PACS in 2014 will be the 200-plus bed community hospital.

New EHR to Lead 2014 Line-Up

In early December Viztek introduced the first platform-agnostic EHR solution. Compatible with MAC, Android, Windows and more, the EHR fully functions at the browser-based level regardless of the operating system or device used. With a modular design to provide facilities with practice management, billing, order entry, PACS, RIS and more, the system is Meaningful Use certified and will relieve medical practices of the costly and complicated system integrations they use today.

“As Viztek looks to 2014, we plan to leverage our core competencies in imaging and IT, combined with the many advances available today in technologic tools and infrastructure, to continue expanding our product line-up and growing our install base in the hospital market. Imaging departments and the referring physician community need advanced and reliable technologies from an innovative partner, and Viztek is answering the call,” proclaimed Cermin. 

For more information on Viztek, visit the company’s website, or see them at HIMSS, booth 4388.

About Viztek

Viztek is a leading provider of complete digital software and hardware imaging solutions, backed by comprehensive training and support for the hospital and private practice markets. The company provides state-of-the-art, web-based Opal-RAD PACS and RIS, delivering advanced connectivity and functionality at an affordable price. The PACS and RIS solutions are complimented by Viztek’s comprehensive line of CR and DR solutions, with DR panels that come in multiple configurations ranging from retrofit packages to complete new radiology rooms and mobile solutions. For more information, visit www.viztek.net.

Around the web

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.